1. Comparative Efficacy of Oral Extended-Release Hydromorphone and Immediate- Release Hydromorphone in Patients with Persistent Moderate to Severe Pain: Two Randomized Controlled Trials 
Alan B. Grosset, MD, MSc, Michael S. Roberts, MD, Mark E. Woodson, MD, Minggao Shi, PhD, Ruth E. Swanton, MPH, Robert F. Reder, MD, Barbara J. Buckley, BA 
Journal of Pain and Symptom Management 
Volume 29, Issue 6, Pages (June 2005)
DOI: /j.jpainsymman
Copyright © 2005 U.S. Cancer Pain Relief Committee Terms and Conditions

2. Fig. 1 Flow diagram for patients enrolled in the study.
Journal of Pain and Symptom Management  , DOI: ( /j.jpainsymman )
Copyright © 2005 U.S. Cancer Pain Relief Committee Terms and Conditions

3. Fig. 2
Least squares means (SE) of API scores by treatment sequence and time of day for the last 2 days of each treatment period during the double-blind phase before the PK/PD day. API rated on a numeric scale ranging from 0 (no pain) to 10 (pain as bad as you can imagine).
Journal of Pain and Symptom Management  , DOI: ( /j.jpainsymman )
Copyright © 2005 U.S. Cancer Pain Relief Committee Terms and Conditions

4. Fig. 3
Mean (SE) number of rescue doses by treatment sequence and time of day for the last 2 days of each treatment period during the double-blind phase before the PK/PD day.
Journal of Pain and Symptom Management  , DOI: ( /j.jpainsymman )
Copyright © 2005 U.S. Cancer Pain Relief Committee Terms and Conditions